New hope for FSGS: experimental drug APL2 enters Late-Stage trial
NCT ID NCT07213960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents will be randomly assigned to receive either APL2 or a placebo. About 270 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FSGS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigator Site 1
Chicago, Illinois, 60643, United States
-
Investigator Site 2
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New biobank aims to unlock why kidney disease returns after transplant
- Can a drug stop kidney disease from returning after transplant?
- Personalized trial matching could revolutionize kidney disease treatment
- New drug aims to calm immune attacks on kidneys
- New study aims to measure swelling in kidney disease patients
- New kidney drug candidate SK-09 enters first human safety tests